Marinomed is a biopharmaceutical company discovering and developing innovative anti-viral and immunological treatments. Marinomed has devoted its discovery and research efforts to the evolution of MAVIREX, a technology platform for the development of therapies that target more than 200 different respiratoryvirus strains based on polymers derived from red seaweed. The huge potential of this technology is reflected by Carragelose©, a unique broadly active anti-viral compound for treating respiratory diseases. Safety and antiviral effectiveness have been established in clinical trials involving both adults and children. The compound is approved for marketing in the EU as part of an anti-viral nasal spray targeting common cold.